Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has released an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced that its subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for generic drugs with its product, Hydrochloride Dopamine Injection. This evaluation by the National Medical Products Administration confirms the quality and therapeutic effects of the generic medication, ensuring its compliance with regulatory standards.
For further insights into HK:0874 stock, check out TipRanks’ Stock Analysis page.
